A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies
Julio C. Barredo(University of Miami), Rajen Mody(University of Michigan), Maria Luisa Sulis(Columbia University Irving Medical Center), Anupam Verma(Primary Children's Hospital), Julie Park(University of California, Los Angeles), Leigh Marcus(Center for Drug Evaluation and Research), Paul S. Gaynon(University of Southern California), Sima Jeha(St. Jude Children's Research Hospital), Richard Sposto(Children's Hospital of Los Angeles), Cecilia Fu, Naomi Winick(The University of Texas Southwestern Medical Center), Jessica A. Pollard(Maine Medical Center), Nobuko Hijiya(Lurie Children's Hospital), Michael J. Burke(Children's Hospital of Wisconsin), Phoenix A. Ho(Medpace (United States)), Rebecca Gardner(Seattle Children's Hospital), Yoav H. Messinger(Children’s Minnesota - St. Paul Hospital), Julia Glade Bender(Columbia University Irving Medical Center), Wendy Y. Tcheng(Children's Hospital Central California), Theodore W. Laetsch(Children's Hospital of Philadelphia), Victor Aquino(The University of Texas Southwestern Medical Center), Weili Sun(City Of Hope National Medical Center), Blythe Thomson(Epizyme (United States)), Thomas Manley(IGM Biosciences (United States))
Cited by 24
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k